Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 3Unknown 2Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × ARX788 × Clear all
NCT02512237 2020-06-05

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Zhejiang Medicine Co., Ltd.

Phase 1 Terminated
9 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡